Virgile Lecoultre1, Guillaume Carrel, Léonie Egli, Christophe Binnert, Andreas Boss, Erin L MacMillan, Roland Kreis, Chris Boesch, Christian Darimont, Luc Tappy. 1. Department of Physiology, University of Lausanne, Lausanne, Switzerland (VL, GC, LE, C Binnert, and LT); the Service of Internal Medicine (GC) and the Service of Endocrinology, Diabetes and Metabolism (LT); Lausanne University Hospital, Lausanne, Switzerland; the Department of Clinical Research and Institute of Diagnostic, Interventional, and Pediatric Radiology, University Bern, Bern, Switzerland (AB, ELM, RK, and C Boesch); and Nutrition & Health Research, Nestlé Research Center, Nestec SA, Lausanne, Switzerland (C Binnert and CD).
Abstract
BACKGROUND: Epidemiologic and experimental data have suggested that chlorogenic acid, which is a polyphenol contained in green coffee beans, prevents diet-induced hepatic steatosis and insulin resistance. OBJECTIVE: We assessed whether the consumption of chlorogenic acid-rich coffee attenuates the effects of short-term fructose overfeeding, dietary conditions known to increase intrahepatocellular lipids (IHCLs), and blood triglyceride concentrations and to decrease hepatic insulin sensitivity in healthy humans. DESIGN: Effects of 3 different coffees were assessed in 10 healthy volunteers in a randomized, controlled, crossover trial. IHCLs, hepatic glucose production (HGP) (by 6,6-d2 glucose dilution), and fasting lipid oxidation were measured after 14 d of consumption of caffeinated coffee high in chlorogenic acid (C-HCA), decaffeinated coffee high in chlorogenic acid, or decaffeinated coffee with regular amounts of chlorogenic acid (D-RCA); during the last 6 d of the study, the weight-maintenance diet of subjects was supplemented with 4 g fructose · kg(-1) · d(-1) (total energy intake ± SD: 143 ± 1% of weight-maintenance requirements). All participants were also studied without coffee supplementation, either with 4 g fructose · kg(-1) · d(-1) (high fructose only) or without high fructose (control). RESULTS: Compared with the control diet, the high-fructose diet significantly increased IHCLs by 102 ± 36% and HGP by 16 ± 3% and decreased fasting lipid oxidation by 100 ± 29% (all P < 0.05). All 3 coffees significantly decreased HGP. Fasting lipid oxidation increased with C-HCA and D-RCA (P < 0.05). None of the 3 coffees significantly altered IHCLs. CONCLUSIONS: Coffee consumption attenuates hepatic insulin resistance but not the increase of IHCLs induced by fructose overfeeding. This effect does not appear to be mediated by differences in the caffeine or chlorogenic acid content. This trial was registered at clinicaltrials.gov as NCT00827450.
RCT Entities:
BACKGROUND: Epidemiologic and experimental data have suggested that chlorogenic acid, which is a polyphenol contained in green coffee beans, prevents diet-induced hepatic steatosis and insulin resistance. OBJECTIVE: We assessed whether the consumption of chlorogenic acid-rich coffee attenuates the effects of short-term fructose overfeeding, dietary conditions known to increase intrahepatocellular lipids (IHCLs), and blood triglyceride concentrations and to decrease hepatic insulin sensitivity in healthy humans. DESIGN: Effects of 3 different coffees were assessed in 10 healthy volunteers in a randomized, controlled, crossover trial. IHCLs, hepatic glucose production (HGP) (by 6,6-d2 glucose dilution), and fasting lipid oxidation were measured after 14 d of consumption of caffeinated coffee high in chlorogenic acid (C-HCA), decaffeinated coffee high in chlorogenic acid, or decaffeinated coffee with regular amounts of chlorogenic acid (D-RCA); during the last 6 d of the study, the weight-maintenance diet of subjects was supplemented with 4 g fructose · kg(-1) · d(-1) (total energy intake ± SD: 143 ± 1% of weight-maintenance requirements). All participants were also studied without coffee supplementation, either with 4 g fructose · kg(-1) · d(-1) (high fructose only) or without high fructose (control). RESULTS: Compared with the control diet, the high-fructose diet significantly increased IHCLs by 102 ± 36% and HGP by 16 ± 3% and decreased fasting lipid oxidation by 100 ± 29% (all P < 0.05). All 3 coffees significantly decreased HGP. Fasting lipid oxidation increased with C-HCA and D-RCA (P < 0.05). None of the 3 coffees significantly altered IHCLs. CONCLUSIONS: Coffee consumption attenuates hepatic insulin resistance but not the increase of IHCLs induced by fructose overfeeding. This effect does not appear to be mediated by differences in the caffeine or chlorogenic acid content. This trial was registered at clinicaltrials.gov as NCT00827450.
Authors: Erikka Loftfield; Meredith S Shiels; Barry I Graubard; Hormuzd A Katki; Anil K Chaturvedi; Britton Trabert; Ligia A Pinto; Troy J Kemp; Fatma M Shebl; Susan T Mayne; Nicolas Wentzensen; Mark P Purdue; Allan Hildesheim; Rashmi Sinha; Neal D Freedman Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-05-21 Impact factor: 4.254
Authors: Jiantao Ma; Micaela C Karlsen; Mei Chung; Paul F Jacques; Edward Saltzman; Caren E Smith; Caroline S Fox; Nicola M McKeown Journal: Nutr Rev Date: 2015-10-29 Impact factor: 7.110
Authors: Samir Softic; Kimber L Stanhope; Jeremie Boucher; Senad Divanovic; Miguel A Lanaspa; Richard J Johnson; C Ronald Kahn Journal: Crit Rev Clin Lab Sci Date: 2020-01-14 Impact factor: 6.250
Authors: Liyuan Han; Wenjie Ma; Dianjianyi Sun; Yoriko Heianza; Tiange Wang; Yan Zheng; Tao Huang; Donghui Duan; J George A Bray; Catherine M Champagne; Frank M Sacks; Lu Qi Journal: Am J Clin Nutr Date: 2017-09-20 Impact factor: 7.045
Authors: Wanessa Costa Silva Faria; Alessandra Almeida da Silva; Natalie Veggi; Nair Honda Kawashita; Suelem A de França Lemes; Wander Miguel de Barros; Edemilson da Conceição Cardoso; Attilio Converti; Waldênia de Melo Moura; Neura Bragagnolo Journal: J Food Drug Anal Date: 2020-06-15 Impact factor: 6.157